RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study is for people with certain blood cancers (like acute myeloid leukemia) that have a specific genetic change called a FLT3 mutation. The cancers have either come back or not responded to prior treatment. The trial tests a combination of three drugs—azacitidine, venetocla…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC